Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates von Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., Köhne, C.-H.

Volltext

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colo... von Folprecht, G., Lutz, M. P., Schöffski, P., Seufferlein, T., Nolting, A., Pollert, P., Köhne, C.-H.

Volltext

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making von Schmoll, H.J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C.J., Balmana, J., Regula, J., Nagtegaal, I.D., Beets-Tan, R.G., Arnold, D., Ciardiello, F., Hoff, P., Kerr, D., Köhne, C.H., Labianca, R., Price, T., Scheithauer, W., Sobrero, A., Tabernero, J., Aderka, D., Barroso, S., Bodoky, G., Douillard, J.Y., El Ghazaly, H., Gallardo, J., Garin, A., Glynne-Jones, R., Jordan, K., Meshcheryakov, A., Papamichail, D., Pfeiffer, P., Souglakos, I., Turhal, S., Cervantes, A.

Volltext

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients von KÖHNE, C.-H, CUNNINGHAM, D, BARON, B, PIGNATTI, F, SCHÖFFSKI, P, MICHEEL, S, HECKER, H, DI COSTANZO, F, GLIMELIUS, B, BLIJHAM, G, ARANDA, E, SCHEITHAUER, W, ROUGIER, P, PALMER, M, WILS, J

Volltext

FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study von Köhne, C.-H, Poston, G, Folprecht, G, Ciardiello, F, Ronga, P, Beier, F, Van Cutsem, E

Volltext

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study von Schultheis, B., Folprecht, G., Kuhlmann, J., Ehrenberg, R., Hacker, U.T., Köhne, C.H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., Fischer, R., Hamann, S., Strumberg, D., Mross, K.B.

Volltext

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in... von Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, S

Volltext

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features von Gaidzik, V I, Teleanu, V, Papaemmanuil, E, Weber, D, Paschka, P, Hahn, J, Wallrabenstein, T, Kolbinger, B, Köhne, C H, Horst, H A, Brossart, P, Held, G, Kündgen, A, Ringhoffer, M, Götze, K, Rummel, M, Gerstung, M, Campbell, P, Kraus, J M, Kestler, H A, Thol, F, Heuser, M, Schlegelberger, B, Ganser, A, Bullinger, L, Schlenk, R F, Döhner, K, Döhner, H

Volltext

Metastatic breast cancer: are we treating the same patients as in the past? von Ufen, M.-P., Köhne, C.H., Wischneswky, M., Wolters, R., Novopashenny, I., Fischer, J., Constantinidou, M., Possinger, K., Regierer, A.C.

Volltext

How to integrate molecular targeted agents in the continuum of care von Köhne, C-H

Volltext

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group von Jahn, N, Agrawal, M, Bullinger, L, Weber, D, Corbacioglu, A, Gaidzik, V I, Schmalbrock, L, Thol, F, Heuser, M, Krauter, J, Göhring, G, Kündgen, A, Fiedler, W, Wattad, M, Held, G, Köhne, C-H, Horst, H-A, Lübbert, M, Ganser, A, Schlenk, R F, Döhner, H, Döhner, K, Paschka, P

Volltext

Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients von Ediebah, D.E., Coens, C., Maringwa, J.T., Quinten, C., Zikos, E., Ringash, J., King, M., Gotay, C., Flechtner, H.-H., Schmucker von Koch, J., Weis, J., Smit, E.F., Köhne, C.-H., Bottomley, A.

Volltext

Current stages of adjuvant treatment of colon cancer von Köhne, C H

Volltext

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal... von KÖHNE, C-H, WILS, J, EL-SERAFI, M, WEISS, U, BURKHARD, O, RÜCKLE, H, LICHINITSER, M, LANGENBUCH, T, SCHEITHAUER, W, BARON, B, COUVREUR, M. L, SCHMOLL, H. J, LORENZT, M, SCHÖFFSKI, P, VOIGTMANN, R, BOKEMEYER, C, LUTZ, M, KLEEBERG, U, RIDWELSKI, K, SOUCHON, R

Volltext

SAT-03 Neoadjuvant treatment of liver metastases von Köhne, C.-H

Volltext

Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and str... von Sorbye, H., Köhne, C.-H., Sargent, D. J., Glimelius, B.

Volltext

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment... von Nordlinger, Bernard, Van Cutsem, Eric, Rougier, Philippe, Köhne, Claus-Henning, Ychou, Marc, Sobrero, Alberto, Adam, Rene, Arvidsson, Dag, Carrato, Alfredo, Georgoulias, Vassilis, Giuliante, Felice, Glimelius, Bengt, Golling, Markus, Gruenberger, Thomas, Tabernero, Josep, Wasan, Harpreet, Poston, Graeme

Volltext

Current perspectives in the treatment of metastatic colorectal cancer von Köhne, C.-H., Folprecht, G.

Volltext

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial von KÖHNE, C-H, CATANE, R, BUGAT, R, FIGE, I, SHANI, A, FAGES, B, DI BETTA, D, JACQUES, C, WILKE, H. J, KLEIN, B, DUCREUX, M, THUSS-PATIENCE, P, NIEDERLE, N, GIPS, M, PREUSSER, P, KNUTH, A, CLEMENS, M

Volltext

Relevance of Ki-67 antigen expression and K- ras mutation in colorectal liver metastases von Petrowsky, H., Sturm, I., Graubitz, O., Kooby, D.A., Staib-Sebler, E., Gog, C., Köhne, C.-H., Hillebrand, T., Daniel, P.T., Fong, Y., Lorenz, M.

Volltext